-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $69

Benzinga·11/20/2026 17:34:55
Listen to the news
JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target from $60 to $69.